Search and analyze individual stocks with comprehensive metrics
Jubilant Pharmova Limited
Fundamental Score
Jubilant Pharmova Limited Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of JUBLPHARMA across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Strong Operating Margins (16.66%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Strong Cash Generation (₹1420.65 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 26.92%)
Observation: Significant professional investor participation indicates quality recognition.
Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
6 factors identified
Below-Average Return on Equity (9.55%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.54%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Limited Growth History (3.90% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Weak Earnings Growth (-9.56% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (-9.56% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Jubilant Pharmova Limited
About JUBLPHARMA
Company Details
Market Information
Performance
JUBLPHARMA Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of JUBLPHARMA?
JUBLPHARMA is currently trading at ₹1097.50 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of JUBLPHARMA shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of JUBLPHARMA and what does it mean?
JUBLPHARMA has a P/E ratio of 35.44x compared to the industry average of 33.97x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹35 for every ₹1 of annual earnings. This is higher than the industry average, suggesting either growth premium or potential overvaluation.
How is JUBLPHARMA performing according to Bull Run's analysis?
JUBLPHARMA has a Bull Run fundamental score of 32.5/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 9.55%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does JUBLPHARMA belong to?
JUBLPHARMA operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Jubilant Pharmova Limited. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for JUBLPHARMA?
JUBLPHARMA has an ROE of 9.55%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Jubilant Pharmova Limited generates profits from shareholders' equity. An ROE of 10% means the company generates ₹10 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is JUBLPHARMA's debt-to-equity ratio and what does it indicate?
JUBLPHARMA has a debt-to-equity ratio of 0.44, which indicates moderate leverage that should be monitored. This means the company has ₹44 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is JUBLPHARMA's dividend yield and is it a good dividend stock?
JUBLPHARMA offers a dividend yield of 0.46%, which means you receive ₹0.46 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has JUBLPHARMA grown over the past 5 years?
JUBLPHARMA has achieved 5-year growth rates of: Sales Growth 3.90%, Profit Growth -9.56%, and EPS Growth -9.56%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in JUBLPHARMA and why does it matter?
Promoters hold 47.68% of JUBLPHARMA shares, with 0.00% of promoter shares pledged. This promoter holding level suggests balanced ownership between management and public shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: -3.00%.
How does JUBLPHARMA compare with its industry peers?
JUBLPHARMA trades at P/E 35.44x vs industry average 33.97x, with ROE of 9.55% and ROCE of 9.54%. The stock trades at a premium to industry average, which may be justified by superior fundamentals. Peer comparison helps identify whether JUBLPHARMA is outperforming its competitive set in profitability, growth, and valuation metrics.
What is JUBLPHARMA's market capitalization and what category does it fall into?
JUBLPHARMA has a market capitalization of ₹17222 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for JUBLPHARMA?
Key ratios for JUBLPHARMA: ROE 9.55% (Needs improvement), ROCE 9.54%, P/E 35.44x, Debt-to-Equity 0.44, Interest Coverage 4.08x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is JUBLPHARMA stock and what is its beta?
JUBLPHARMA has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for JUBLPHARMA?
JUBLPHARMA has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹1097.50, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in JUBLPHARMA?
Key risks for JUBLPHARMA include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.44), and operational challenges. The stock has a Fundamental Score of 32.5/100, indicating higher risk requiring thorough due diligence. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is JUBLPHARMA's operating profit margin and how has it trended?
JUBLPHARMA has a 5-year average Operating Profit Margin (OPM) of 16.66%, which is good and shows decent operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. This strong margin indicates competitive advantages and operational leverage. Compare with industry peers to understand relative performance.
How is JUBLPHARMA's quarterly performance in terms of sales and profit growth?
JUBLPHARMA's recent quarterly performance shows YoY Sales Growth of 9.76% and YoY Profit Growth of -3.72%. Growth rates indicate the current business trajectory and market demand. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in JUBLPHARMA?
JUBLPHARMA has FII holding of 17.40% and DII holding of 9.52%, totaling 26.92% institutional ownership. This institutional participation level shows the confidence of professional money managers. Significant FII holding suggests global investor confidence and potential for index inclusion. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.